Brightex Bio-Photonics, LLC v. L'Oreal USA, Inc.

CourtDistrict Court, N.D. California
DecidedMay 7, 2025
Docket3:24-cv-07919
StatusUnknown

This text of Brightex Bio-Photonics, LLC v. L'Oreal USA, Inc. (Brightex Bio-Photonics, LLC v. L'Oreal USA, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Brightex Bio-Photonics, LLC v. L'Oreal USA, Inc., (N.D. Cal. 2025).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 BRIGHTEX BIO-PHOTONICS, LLC, 7 Case No. 24-cv-07919-JCS Plaintiff, 8 v. ORDER GRANTING RULE 54(b) 9 MOTION L'OREAL USA, INC., 10 Re: Dkt. No. 39 Defendant. 11

12 13 I. INTRODUCTION 14 In this action, Plaintiff Brightex Bio-Photonics, LLC (“Brightex”) accuses Defendant 15 L’Oreal USA, Inc. (“L’Oreal USA”) of infringing two of its patents: U.S. Patent No. 9,842,358 16 (“the `358 Patent”) and U.S. Patent No. 9,542,595 (“the `595 Patent”). On March 6, 2025, the 17 Court granted L’Oreal’s motion to dismiss under 35 U.S.C. § 101 and Alice Corp. Pty. Ltd. v. CLS 18 Bank Int’l, 573 U.S. 208 (2014) as to the ’358 Patent and dismissed Brightex’s claim of 19 infringement of that patent with prejudice. Dkt. no. 32 (“March 6 Order”). Brightex now brings a 20 Rule 54(b) Motion (“Motion”), asking the Court to enter final judgment on its claim of 21 infringement of the ’358 Patent so that it can pursue an immediate appeal without waiting for the 22 Court to adjudicate Brightex’s claim of infringement of the ’595 Patent. The Court finds that the 23 Motion is suitable for determination without oral argument and therefore vacates the motion 24 hearing set for May 14, 2025 pursuant to Civil Local Rule 7-1(b). For the reasons stated below, 25 the Motion is GRANTED.1 26 27 1 II. BACKGROUND 2 A. The Complaint2 3 According to Brightex’s founder and Chief Executive Officer, the ’358 and ’595 Patents 4 “relate generally to providing skin treatment recommendations to an end user by analyzing a 5 digital image of the user, identifying relevant skin characteristics of the user, and selecting a skin 6 treatment recommendation for the user based on the identified skin characteristics.” Compl. ¶ 81. 7 While the general subject matter of the two patents is the same, they are not related and have 8 different specifications and claims. See generally Compl. Ex. 1 (’358 Patent) & 2 (’595 Patent). 9 Brightex alleges that L’Oreal is infringing the ’358 and ’595 Patents on various websites and 10 applications. Compl. ¶¶ 85, 107. A number of the websites and applications are alleged to 11 infringe both patents. Id. 12 B. Contentions of the Parties 13 1. The Motion 14 In the Motion, Brightex asserts that final judgment should be entered as to the ’358 Patent 15 under Rule 54(b) because “[t]here is no dependence or interrelationship between the Court’s 16 March 6, 2025 patent ineligibility determination for the ‘358 Patent and the on-going claims of the 17 ‘595 Patent infringement claims in this matter[.]” Motion at 1. Brightex further asserts that “the 18 nature of the Court’s March 6, 2025 Dismissal Order means that no appellate court would have to 19 decide the same issues more than once even if there are subsequent appeals relating to another 20 asserted patent.” Id. 21 First, Brightex contends the Court’s March 6 Order is “an ultimate disposition of an 22 individual claim entered in the course of a multiple claims action.” Id. at 4 (quoting W.L. Gore & 23 Assocs., Inc. v. Int'l Med. Prosthetics Rsch. Assocs., Inc., 975 F.2d 858, 861 (Fed. Cir. 1992); 24 Sears, Roebuck & Co. v. Mackey, 351 U.S. 427, 436 (1956); Tessera, Inc. v. Toshiba Corp., No. 25 15-CV-02543-BLF, 2017 WL 11002227, at *3 (N.D. Cal. Mar. 6, 2017)). 26 Next, Brightex argues that there is no just reason for delay because the claims are separate 27 1 and therefore, the appellate court would not have to decide the same issue more than once even if 2 there were subsequent appeals. Id. at 5 (citing Curtiss-Wright Corp. v. General Elec. Co., 446 3 U.S. 1, 8 (1980)). Brightex points to the Court’s March 6 Order, asserting that the Court “focused 4 exclusively on patent eligibility of the ‘358 Patent under Section 101, as interpreted under the 5 Alice decision and its progeny” and that its “Section 101 patent eligibility analysis of the ‘358 6 Patent was solely based on the ‘358 Patent itself – nothing else.” Id. According to Brightex, 7 “[t]here is no dependence or interrelationship between the Court’s determination on patent 8 ineligibility of the ‘358 Patent under Section 101 and any appellate issues that might be raised in 9 the future with respect to the ‘595 Patent” because “any appellate issues relating to claim 10 construction, infringement, validity, or enforceability of the ‘595 Patent would be irrelevant to the 11 appellate consideration of the ‘358 Patent under Section 101.” Id. at 5-6. 12 Brightex further contends its request for entry of Rule 54(b) judgment is supported by 13 equitable factors. Id. at 6 (citing Lexos Media IP, LLC v. EBay Inc., 3:23-cv-06314-RFL, Dkt. 14 138 (N.D. Cal. May 13, 2024) (Motion Ex. 1)). First, it asserts that the March 6 Order has placed 15 a “cloud” over its ’358 Patent and therefore, it should be allowed to appeal the Court’s order 16 immediately. Id. at 7. 17 Next, Brightex points out that the life of a patent is limited and so a delayed appeal will 18 reduce the value of its patent even if it is ultimately found to be valid on appeal. Id. Brightex 19 suggests L’Oreal may not be committed to expeditious litigation of the ’595 Patent infringement 20 claim, pointing to L’Oreal’s request for a 30-day extension on the deadline to file an answer as to 21 that claim. Id. 22 Third, Brightex contends “granting this Rule 54(b) request would not prejudice Defendant 23 L’Oreal because L’Oreal will need to address the Section 101 ruling on the ‘358 Patent on appeal 24 either sooner or later.” Id. at 8. Brightex points to Tessera, Inc. v. Toshiba Corp., arguing that 25 L’Oreal will not be prejudiced by entry of a 54(b) judgment in this case “because both ‘parties are 26 sophisticated technology companies . . . , neither party points to concrete consequences that 27 granting or denying certification would have on its interests[,] [and] [t]here is also no suggestion 1 Id. (quoting Tessera, No. 15-CV-02543-BLF, 2017 U.S. Dist. LEXIS 223671 at *22 (N.D. Cal. 2 Mar. 6, 2017)). 3 2. Opposition 4 In its Opposition, L’Oreal does not challenge Brightex’s assertion that the first requirement 5 for entry of a 54(b) judgment is met, namely, that as to the ’358 Patent, the March 6 Order is, in 6 effect, a final judgment that leaves nothing to be decided. It argues, however, that allowing an 7 immediate appeal of the March 6 Order is not in the interest of judicial economy or supported by 8 the equities. Opposition at 1, 5-6. 9 First, L’Oreal rejects Brightex’s contention that the two patent infringement claims are 10 “wholly independent” of one another, pointing out that Brightex “has accused many of the same 11 websites of infringing both patents.” Id. at 1. L’Oreal acknowledges that “Brightex might argue 12 that different aspects of these websites are accused for each patent,” but argues that “both patents 13 relate to the same basic functionalities—analyzing or manipulating images of a person’s face for 14 the purpose of recommending products.” Id. Furthermore, L’Oreal asserts, “any infringement 15 trial on the ’595 patent will require fact and expert testimony and evidence as to the structure, 16 operation, and use of the accused websites, including what features and functionalities drive 17 demand for or profitability of the websites (e.g., by comparing the accused features with other 18 patented and unpatented features).” Id. Because the same testimony and evidence would also be 19 necessary if the dismissal under § 101 of the ’358 Patent were overruled and that claim went to 20 trial, L’Oreal asserts that if “Brightex wants to appeal the ’358 patent dismissal now, judicial 21 economy warrants staying the remainder of the case in the interim.” Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Georgia v. Brailsford
3 U.S. 1 (Supreme Court, 1794)
Catlin v. United States
324 U.S. 229 (Supreme Court, 1945)
Sears, Roebuck & Co. v. MacKey
351 U.S. 427 (Supreme Court, 1956)
Curtiss-Wright Corp. v. General Electric Co.
446 U.S. 1 (Supreme Court, 1980)
McCulloch v. Maryland
17 U.S. 159 (Supreme Court, 1819)
Payne v. Wickliffe
9 Ky. 5 (Court of Appeals of Kentucky, 1819)

Cite This Page — Counsel Stack

Bluebook (online)
Brightex Bio-Photonics, LLC v. L'Oreal USA, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/brightex-bio-photonics-llc-v-loreal-usa-inc-cand-2025.